Description

Novoparin solution for injections 60 mg. syringe 0.6 ml. №2

Ingredients

Novoparin solution for injections contains 60 mg of the active ingredient, which is typically enoxaparin sodium. Other ingredients may include water for injection, sodium chloride, and benzyl alcohol.

Dosage

The recommended dosage of Novoparin solution for injections is determined by the healthcare provider based on the patient’s condition, weight, and other factors. It is typically administered subcutaneously once or twice daily.

Indications

Novoparin solution for injections is commonly used for the prevention and treatment of blood clots in conditions such as deep vein thrombosis, pulmonary embolism, and during certain surgical procedures.

Contraindications

Patients with a known hypersensitivity to enoxaparin or any of the ingredients in Novoparin solution should not use this medication. It is also contraindicated in patients with active major bleeding.

Directions

Novoparin solution for injections should be administered as directed by a healthcare professional. The injection site should be rotated, and the injection should be given at the same time each day to maintain consistent levels of the medication in the blood.

Scientific Evidence

Studies have shown that enoxaparin, the active ingredient in Novoparin solution for injections, is effective in preventing blood clots and reducing the risk of thromboembolic events. Research published in the Journal of Thrombosis and Haemostasis demonstrated the efficacy of enoxaparin in various clinical settings.

Additional Information

It is important to monitor for signs of bleeding while using Novoparin solution for injections. Patients should report any unusual bruising or bleeding to their healthcare provider. Additionally, dosage adjustments may be necessary for patients with renal impairment.

Pharmacological Effects: Enoxaparin works by inhibiting the formation of blood clots. It acts as an anticoagulant by binding to antithrombin III, which inactivates several clotting factors, thereby preventing the formation of new clots and reducing the risk of existing clots growing larger.

Clinical Trials: Clinical trials have demonstrated the safety and efficacy of enoxaparin in various patient populations. A study published in the New England Journal of Medicine showed that enoxaparin was as effective as unfractionated heparin in preventing deep vein thrombosis in patients undergoing hip replacement surgery.